clinical trial · NCT05071937

ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

Alexander B Olawaiye, MD·phase2·recruiting·n = 33

Ovarian CancerPeritoneal CancerFallopian Tube CancerZEN003694Talazoparib

brief summary

This Phase 2, open label, study with safety lead in of oral talazoparib in combination with ZEN003694 given daily in 28-day cycles will enroll patients with recurrent ovarian, fallopian tube or primary peritoneal carcinoma.

started

Apr 21, 2023

primary completion

Dec 31, 2031

completion

Mar 1, 2033

last updated

Jun 22, 2025

detailed description

This study aims to determine how effective the combination of ZEN003694 and talazoparib is based on how patients respond. ZEN003694 (and developed by Zenith Epigenetics Ltd.) has shown promising activity in the treatment of solid tumors and hematologic (blood) cancers by reducing the multiplication of cancer cells. Talazoparib is an extremely effective drug being developed for the treatment of a variety of human cancers. Talazoparib kills cancer cells by inhibiting and trapping the enzyme PARP, which is known to be involved in the development of many types of cancers. These two drugs are not FDA approved in the treatment of ovarian cancer.

official title

Phase ll Study of a BET Inhibitor, ZEN003694, Combined With a PARP Inhibitor, Talazoparib, in Patients With Recurrent Ovarian Cancer

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol